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resources and work productivity were also recorded. RESULTS:
The sample for this analysis was composed of patients treated
with GBP (n = 44) and a random sample of 88 patients treated
with PGB and matched for age, sex, and clinical characteristics.
Mean (SD) doses for GBP and PGB were 1263 (540) and 202
(119) mg/day, respectively. Patients treated with PGB showed
greater reduction in pain intensity compared with GBP patients
(39  23 vs 28  22 mm in the VAS SF-MPQ; p = 0.008), yield-
ing to a higher signiﬁcantly proportion of patients with a 50%
reduction of baseline pain at the end of the study; 41% vs. 61%,
respectively; p = 0.029. The remaining patient-reported out-
comes improved signiﬁcantly and to a similar extent after treat-
ment with either drug. The signiﬁcantly higher drug cost of PGB
as compared with GBP was traded-off with the greater reduction
in productivity cost in the former group. CONCLUSIONS: Both
drugs were associated with a similar reduction of costs. However,
results suggest that pregabalin showed a greater effectiveness
than gabapentin in the control of NeP. These differences may
reﬂect greater difﬁculties in reaching the therapeutic dose for
gabapentin in routine medical practice.
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OBJECTIVES: One of the challenges for innovation in chronic
pain treatment is to provide consistent pain control over a 24-hour
period. How does this clinical objective translate into concepts
relevant to patients, and do the existing instruments adequately
capture these concepts? METHODS: Thirty face-to-face explor-
atory interviews were conducted by psychologists in France,
Germany and the UK with patients with chronic pain (cancer-
related pain excluded) to collect information on how they describe
the course of pain over 24 hours and how changes in pain levels
and the time they occur affects their everyday lives. In parallel, a
list of related concepts and a description of the conceptual con-
tents of existing instruments was extracted from the literature.
RESULTS: Analysis of the patient interviews resulted in the
identiﬁcation of several concepts related to 24-hour pain control
which are closely intertwined with one another: type of pain
(background, breakthrough, and end-of-dose pain), description
(occurrence, intensity, sensation), worsening, relieving, triggering
factors, impact of pain (particularly patients’ activities of daily
living, sleep andmood), pain medication (efﬁcacy, time to efﬁcacy,
duration of efﬁcacy, frequency medication is taken) and pain over
time (evolution over one day).Most of these concepts are partially
or extensively covered by existing instruments. However, no
instrument is comprehensive enough to be used as a standalone
measure. CONCLUSIONS: The control of 24-hour pain is
complex and requires multidimensional assessment. Despite the
considerable number of pain questionnaires available, no speciﬁc
measurement instrument exists that fully addresses the concerns
of patients. To accurately capture the beneﬁts of once-daily treat-
ments in pain control, researchers need either a new instrument, or
the adaptation of a series of existing questionnaires to form a
consistent and comprehensive battery.
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OBJECTIVES: To analyze prospectively the effect of adding Pre-
gabalin (PGB) on PRO measurements evolution in the treatment
of refractory Low Back Pain under routine medical practice
conditions. METHODS: Post-hoc analysis of patients above 18
years, with 6-month chronic Low Back pain refractory to, at
least, one previous analgesic [previous mean (SD) number of
drugs was 2.1 (1.3), 22.7% on one-drug], included in a prospec-
tive, naturalistic, 12-weeks two-visit study. This analysis com-
pared patients receiving PGB as an add-on therapy (PGB add-on)
versus subjects receiving any other analgesic pattern not includ-
ing PGB (non-PGB). PRO measurements included evaluation of
severity and interference of pain (Brief Pain Inventory), anxiety
and depression symptoms (HAD scale), and quality-of-life (SF-
12). RESULTS: A total of 683 [49.5% women, 55.0 (12.7) years]
patients were analyzed: 82.6% received PGB add-on and 17.4%
non-PGB. Twelve weeks therapy with PGB add-on was associ-
ated with higher reduction in pain severity than in non-PGB; -3.4
(2.0) pts, 61.6% responders (350% baseline pain reduction) vs.
-2.0 (2.1), 37.3% responders; p < 0.0001, respectively. Pain
interference was also reduced more with PGB add-on: -3.5 (2.1)
pts vs. -2.0 (2.3), respectively; p < 0.0001, and showed greater
reduction in depression [-4.0 (4.1) pts vs. -2.1 (3.3); p < 0.0001]
and anxiety [-3.7 (3.6) pts vs. -1.9 (3.0); p < 0.0001] symptoms
scores, yielding to a signiﬁcant improvement in patient’s quality
of life: mental and physical summary components change were
higher in PGB add-on therapy group: +7.3 (10.6) vs. +2.0 (7.4);
p < 0.0001, and +9.7 (9.6) vs. +5.8 (8.3); p < 0.0001, respec-
tively. CONCLUSIONS: Compared with adding other any drug,
the addition of PGB to the treatment pattern of refractory Low
Back Pain seems to be associated with higher improvement in
PRO measurements, including reduction of pain severity and
interference and improvement of quality of life under routine
medical practice condition.
PSY52
QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY
COAGULOPATHIES. INTERMEDIATE RESULTS
Vorobyev P1, Borisenko O2, Zhulev U3, Kopylov K4,Telnova E5,
Tonoyan A2
1Moscow Medical Academy named after I.M.Sechenov, Moscow,
Russia, 2Russian Society for Pharmacoeconomics and Outcomes
Research, Moscow, Russia, 3All-Russian Hemophilia Society, Moscow,
Russia, 4Hematological Research Center, Moscow, Russia,
5Roszdravnadzor, Moscow, Russia
OBJECTIVES: The Government of Russian Federation provided
up to US$377 million to the management of hereditary coagulo-
pathies (hemophilia type A and type B, von Willebrand’s disease)
since 2008. The amount of ﬁnancing to the custom of coagula-
tion factors increased 20 times for 2004–2008, and at
the present, aggregate 3.49 IU of clotting factor VIII fall on one
citizen of Russia. Russian Society of Pharmacoeconomics and
Outcomes Research jointly with the All-Russian Hemophilia
Society made the ﬁrst Russian postal survey of all registered
Abstracts A645
